CAM
FLGT icon

Concorde Asset Management’s Fulgent Genetics FLGT Stock Holding History

Concorde Asset Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,343
Closed -$1.04M – 170
2021
Q4 		$1.04M Buy
10,343
+114
+1% +$10K 0.62% 54
2021
Q3 		$920K Buy
10,229
+7,973
+353% +$725K 0.53% 62
2021
Q2 		$208K Sell
2,256
-1,781
-44% -$142K 0.12% 182
2021
Q1 		$390K Sell
4,037
-24,472
-86% -$2.53M 0.22% 111
2020
Q4 		$1.49M Buy
28,509
+7,086
+33% +$296K 0.82% 33
2020
Q3 		$858K Buy
+21,423
New +$671K 0.49% 60

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Concorde Asset Management's FLGT Position: Q1 2022 in Review

Concorde Asset Management sold out of Fulgent Genetics (FLGT) in Q1 2022, closing a stake of 10,343 shares — an estimated $1.04M sold.

Concorde Asset Management first reported a position in FLGT in Q3 2020 and held it in 6 quarters. The position peaked at $1.49M in Q4 2020. 275 funds tracked by Wall St. Rank hold FLGT as of Q1 2022.

  • Concorde Asset Management reported no remaining Fulgent Genetics position as of Q1 2022 after selling out during the quarter.
  • Concorde Asset Management sold 10,343 Fulgent Genetics shares in Q1 2022, an estimated $1.04M.
  • Concorde Asset Management first reported a position in Fulgent Genetics in Q3 2020 and held it in 6 quarters.
  • Concorde Asset Management's Fulgent Genetics position peaked at $1.49M in Q4 2020.
  • 275 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2022.

Based on Concorde Asset Management's 13F filing for Q1 2022, filed 22 Apr 2022.